About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiovascular
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
Treatment Considerations in T2D
Playback speed
0.5x
0.75x
1x (Normal)
1.25x
1.5x
1.75x
2x
10 seconds
Y
SGLT2 inhibitors and GLP-1 agonists: Why Are They Important and Which Do I Choose?
By
13th Orange County Symposium for Cardiovascular Disease Prevention
FEATURING
Yehuda Handelsman
By
13th Orange County Symposium for Cardiovascular Disease Prevention
FEATURING
Yehuda Handelsman
3,432 views
January 27, 2022
4 Comments
Login to view comments.
Click here to Login
30:23
The Texas Heart Institute
Update of Diabetes Treatment: Overview of Current Trials and ADA Pra…
Feat.
D. Aguilar
17:15
Houston Methodist DeBakey Heart and Vascular Center
Practical Tips for Managing CVD Risk Among High-Risk Diabetes
Feat.
M. Blaha
17:43
Houston Methodist DeBakey Heart and Vascular Center
Q&A: CVD Prevention in Diabetes
Feat.
G. Bakris,
K. Patel,
A. Kansara,
I. Lingvay,
N. Pagidipati
54:59
Scripps Health
Cost-Effective Diabetes Care: Strategies for T2D Management
Feat.
M. J. Levine
14:52
ACC 2022 Conference Coverage
ACC 2022: An Overview of SGLT2i and GLP1 RA Use in Cardiovascular Di…
Feat.
R. Eckel
18:15
Canadian Collaborative Research Network
GLP-1 Agonists: Underused and Underappreciated?
Feat.
D. K. Mcguire
